Medications available on the MyRx Care™ Patient Financial Assistance Portal
The MyRx Care™ Patient Financial Assistance Portal covers the following medications: Amgen Amgevita®Avsola®Repatha®Evenity®Enbrel® PharmascienceFingolimodAbirateroneDimethyl FumarateFampridineTeriflunomidePazopanibApremilastTofacitinib PendopharmGlatect™ FerringFirmagon
Patient education: what is the cold chain for biosimilars and biologics?
The cold chain is an essential aspect of pharmaceutical distribution in Canada. A cold chain is a series of temperature-controlled facilities, vehicles, and procedures that ensure the safe transportation and storage of pharmaceutical products. The maintenance of a cold chain is vital to protect the…
Canadian patients and biosimilars: A guide to talking to your pharmacist
The Ontario Drug Benefit (ODB) is expanding the use of biosimilars starting on March 31, 2023. This means that patients who were covered by certain biologics such as Humira® will have coverage switched to a biosimilar. This is a great time for patients to get…
Pharmacy practice: How pharmacists manage care for patients taking biosimilars
Pharmacists play a critical role in managing care for patients taking biosimilars. Biosimilars are a newer class of drugs that are designed to be similar to biologics, but they are not exact copies of the original biologic. They offer a more affordable option for patients…
The role of pharmacists in educating Canadian patients about biosimilars
Pharmacists are critical healthcare professionals who play a crucial role in educating patients about biosimilars and promoting their use. As a type of biological medication that is highly similar to an existing biologic drug, biosimilars have the potential to provide more affordable and accessible treatment…
The importance of patient education and awareness campaigns around biosimilars to reduce stigma in Canada
Biosimilars are a type of biological medication that are highly similar to an existing biologic drug. These medications have the potential to provide more affordable and accessible treatment options for patients in Canada, yet uptake has been slower than expected. Patient education and awareness campaigns…
The impact of biosimilars on the biopharmaceutical industry and their potential to promote innovation
The biopharmaceutical industry is an essential component of the global healthcare system, providing life-saving treatments for a wide range of conditions. However, the high cost of many biologic drugs has become a significant challenge for patients, healthcare providers, and payers alike. The introduction of biosimilars…
The difference between biologics and biosimilars
Biologics and biosimilars are both types of drugs used in the treatment of various medical conditions, including cancer, autoimmune diseases, and chronic conditions like rheumatoid arthritis. Biologics are a type of medication that is made from living organisms or biological substances, such as proteins or…
Why biosimilars are important to Canadians
Biosimilars are a growing and increasingly important topic for Canadians, and there are several reasons why these medications are so important for our healthcare system. In short, biosimilars are generic versions of biologic drugs, which are drugs made from living organisms. Unlike traditional generic drugs,…
Patient education: services provided by assistance programs for patients taking biosimilars
Biosimilars are a newer class of drugs that are designed to be similar to biologics, but they are not exact copies of the original biologic. Biosimilars offer a more affordable option for patients who need treatment for chronic and life-threatening conditions, but they can also…
